Literature DB >> 10523621

DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter.

C De Smet1, C Lurquin, B Lethé, V Martelange, T Boon.   

Abstract

A subset of male germ line-specific genes, the MAGE-type genes, are activated in many human tumors, where they produce tumor-specific antigens recognized by cytolytic T lymphocytes. Previous studies on gene MAGE-A1 indicated that transcription factors regulating its expression are present in all tumor cell lines whether or not they express the gene. The analysis of two CpG sites located in the promoter showed a strong correlation between expression and demethylation. It was also shown that MAGE-A1 transcription was induced in cell cultures treated with demethylating agent 5'-aza-2'-deoxycytidine. We have now analyzed all of the CpG sites within the 5' region of MAGE-A1 and show that for all of them, demethylation correlates with the transcription of the gene. We also show that the induction of MAGE-A1 with 5'-aza-2'-deoxycytidine is stable and that in all the cell clones it correlates with demethylation, indicating that demethylation is necessary and sufficient to produce expression. Conversely, transfection experiments with in vitro-methylated MAGE-A1 sequences indicated that heavy methylation suffices to stably repress the gene in cells containing the transcription factors required for expression. Most MAGE-type genes were found to have promoters with a high CpG content. Remarkably, although CpG-rich promoters are classically unmethylated in all normal tissues, those of MAGE-A1 and LAGE-1 were highly methylated in somatic tissues. In contrast, they were largely unmethylated in male germ cells. We conclude that MAGE-type genes belong to a unique subset of germ line-specific genes that use DNA methylation as a primary silencing mechanism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523621      PMCID: PMC84726          DOI: 10.1128/MCB.19.11.7327

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  53 in total

1.  The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation.

Authors:  C De Smet; O De Backer; I Faraoni; C Lurquin; F Brasseur; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

Review 2.  CpG islands and genes.

Authors:  S H Cross; A P Bird
Journal:  Curr Opin Genet Dev       Date:  1995-06       Impact factor: 5.578

3.  A role for nuclear NF-kappaB in B-cell-specific demethylation of the Igkappa locus.

Authors:  A Kirillov; B Kistler; R Mostoslavsky; H Cedar; T Wirth; Y Bergman
Journal:  Nat Genet       Date:  1996-08       Impact factor: 38.330

4.  DNA methylation directs a time-dependent repression of transcription initiation.

Authors:  S U Kass; N Landsberger; A P Wolffe
Journal:  Curr Biol       Date:  1997-03-01       Impact factor: 10.834

5.  Asymmetric methylation in the hypermethylated CpG promoter region of the human L1 retrotransposon.

Authors:  D M Woodcock; C B Lawler; M E Linsenmeyer; J P Doherty; W D Warren
Journal:  J Biol Chem       Date:  1997-03-21       Impact factor: 5.157

6.  Sequence and expression pattern of the human MAGE2 gene.

Authors:  C De Smet; C Lurquin; P van der Bruggen; E De Plaen; F Brasseur; T Boon
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

7.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.

Authors:  Y T Chen; M J Scanlan; U Sahin; O Türeci; A O Gure; S Tsang; B Williamson; E Stockert; M Pfreundschuh; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 8.  Alterations in DNA methylation: a fundamental aspect of neoplasia.

Authors:  S B Baylin; J G Herman; J R Graff; P M Vertino; J P Issa
Journal:  Adv Cancer Res       Date:  1998       Impact factor: 6.242

9.  Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene.

Authors:  C De Smet; S J Courtois; I Faraoni; C Lurquin; J P Szikora; O De Backer; T Boon
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

10.  Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis.

Authors:  K Takahashi; S Shichijo; M Noguchi; M Hirohata; K Itoh
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

View more
  189 in total

1.  Identification of novel small molecules that inhibit protein-protein interactions between MAGE and KAP-1.

Authors:  Neehar Bhatia; Bing Yang; Tony Z Xiao; Noel Peters; Michael F Hoffmann; B Jack Longley
Journal:  Arch Biochem Biophys       Date:  2011-01-28       Impact factor: 4.013

2.  Fidelity of the methylation pattern and its variation in the genome.

Authors:  Toshikazu Ushijima; Naoko Watanabe; Eriko Okochi; Atsushi Kaneda; Takashi Sugimura; Kazuaki Miyamoto
Journal:  Genome Res       Date:  2003-05       Impact factor: 9.043

3.  Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.

Authors:  Rani E George; Jill M Lahti; Peter C Adamson; Kejin Zhu; David Finkelstein; A Mark Ingle; Joel M Reid; Mark Krailo; Donna Neuberg; Susan M Blaney; Lisa Diller
Journal:  Pediatr Blood Cancer       Date:  2010-10       Impact factor: 3.167

4.  Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.

Authors:  Amberly Moreno-Bost; Susann Szmania; Katie Stone; Tarun Garg; Antje Hoerring; Jackie Szymonifka; John Shaughnessy; Bart Barlogie; H Grant Prentice; Frits van Rhee
Journal:  Cytotherapy       Date:  2010-12-20       Impact factor: 5.414

5.  Helicobacter pylori, a carcinogen, induces the expression of melanoma antigen-encoding gene (Mage)-A3, a cancer/testis antigen.

Authors:  Takashi Fukuyama; Taiga Yamazaki; Tomoko Fujita; Takayuki Uematsu; Yoshinobu Ichiki; Hiroshi Kaneko; Tatsuo Suzuki; Noritada Kobayashi
Journal:  Tumour Biol       Date:  2012-07-07

6.  A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.

Authors:  Yan Yan; Leuyen Phan; Fan Yang; Moshe Talpaz; Yu Yang; Zeyu Xiong; Bernard Ng; Nikolai A Timchenko; Catherine J Wu; Jerome Ritz; Hong Wang; Xiao-Feng Yang
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

7.  MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair.

Authors:  Neehar Bhatia; Tony Z Xiao; Kimberly A Rosenthal; Imtiaz A Siddiqui; Saravanan Thiyagarajan; Brendan Smart; Qiao Meng; Cindy L Zuleger; Hasan Mukhtar; Shannon C Kenney; Mark R Albertini; B Jack Longley
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

8.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

Review 9.  Antigen-specific vaccines for cancer treatment.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Tissue specific differentially methylated regions (TDMR): Changes in DNA methylation during development.

Authors:  Fei Song; Saleh Mahmood; Srimoyee Ghosh; Ping Liang; Domminic J Smiraglia; Hiroki Nagase; William A Held
Journal:  Genomics       Date:  2008-11-13       Impact factor: 5.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.